New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial documentation and execution. ATLANTA, GA, UNITED ...
Investing.com - Barclays has maintained its Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a price target of $44.00, representing nearly 79% upside from the current price of $24.61.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results